Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Liposomal doxorubicin (Caelyx‚) in the treatment of recurrent high-grade glioma – a phase I/II study

Liposomal doxorubicin (Caelyx‚) in the treatment of recurrent high-grade glioma – a phase I/II study. Proceedings of the American Society of Clinical Oncology (ASCO) 36. 2000; 36:661.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.